Thumbnail Image
Publication

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Petrylak, D
; 
Vogelzang, N
; 
Budnik, N
; 
Wiechno, P
; 
Sternberg, C
; 
Doner, K
; 
Bellmunt, J
; 
Burke, J
; 
de Olza, M
; 
Choudhury, Ananya
... show 10 more
Citations
Altmetric:
Abstract
Patients with metastatic castration-resistant prostate cancer have few treatment options. We investigated the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Authors
Petrylak, D
Vogelzang, N
Budnik, N
Wiechno, P
Sternberg, C
Doner, K
Bellmunt, J
Burke, J
de Olza, M
Choudhury, Ananya
Gschwend, J
Kopyltsov, E
Flechon, A
Van As, N
Houede, N
Barton, D
Fandi, A
Jungnelius, U
Li, S
de Wit, R
Fizazi, K
Affiliation
Yale Cancer Center, Department of Medicine Division of Oncology, New Haven, CT, USA
Description
Date
2015-03-02
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. 2015: Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/346887
Embedded videos